Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.

J Immunother Cancer · 2019 · PMC6362598 · PMID 30717797

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

In this study, clinical activity was seen both in PD-L1+ and PD-L1− tumors including similar ORR and PFS and a nonsignificant trend in the 1 L-mn subgroup for longer OS in PD-L1+ tumors.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.